Novocure, the Swiss maker of a wearable electric field therapy to treat certain cancers, has named veteran insider Frank ...

Imvax has shrugged off the failure of its phase 2b brain cancer trial to hit its primary endpoint, reporting evidence of ...

Tiziana Life Sciences has pointed to increased Big Pharma interest in the IL-6 pathway as justification for its ...

Makary announced in May that he intended for the FDA to fully integrate generative AI into its work by the end of June; that ...

Angelini’s investments will be made through its Angelini Ventures arm. EIB and Angelini plan to support between seven and 10 ...

Akebia Therapeutics has struck a deal for Q32 Bio’s deprioritized complement | Akebia Therapeutics has struck a deal for Q32 ...

Belite linked tinlarebant to a 35.7% reduction in lesion growth rate versus placebo, achieving the study’s primary endpoint.

Regeneron is adding its name to Tessera Therapeutics’ unique in vivo gene writing program, inking a deal that lets it in on a ...

Though artificial intelligence has long made a name for itself in imaging—with hundreds of programs able to automate separate ...

Researchers said they have uncovered a novel sign of chronic stress and its damaging effects on the body by using an ...

Protego Biopharma is gearing up to bring its amyloid light-chain (AL) amyloidosis prospect into pivotal testing using its new ...

Clinical trials succeed or stall based on one factor that’s easy to overlook: how well they fit into patients’ lives. | ...